Biohaven Pharmaceutical Holding Company Limited (d/b/a Biohaven) announced today that preliminary results from a Phase I study with BHV-0223, a glutamate modulating agent, met its study objectives and supports advancing the asset into late phase … Read More»
Biohaven Announces Phase 1 Pharmacokinetic Study Meets Study Objectives and Supports Advancing BHV-0223
Biohaven Appoints Vlad Coric M.D. as Chief Executive Officer
The Board of Directors of Biohaven Pharmaceutical Holding Company Limited (d/b/a Biohaven) is pleased to announce the election of Vlad Coric, M.D. as Chief Executive Officer. Dr. Coric has had a distinguished academic and pharmaceutical career with … Read More»
Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV‑0223
TORONTO, Oct. 6, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that Biohaven has completed the multiple … Read More»
Biohaven and Fox Chase Chemical Diversity Center Announce Strategic Alliance in Early Stage Drug Discovery Research
TORONTO, Oct. 1, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce a strategic alliance with ALS … Read More»
Biohaven Doses First Human Subject In Phase 1 Trial With Lead Drug Candidate BHV-0223
Toronto, Ontario, August 27, 2015 – Portage Biotech Inc. (“Portage”) (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that dosing has commenced in a Phase I … Read More»
Biohaven Acquires Intellectual Property For Portfolio Of Prodrugs From ALS Biopharma, LLC
Toronto, Ontario, August 18, 2015 – Portage Biotech Inc. (“Portage”) (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U) and Biohaven Pharmaceutical Holding Company Limited (“Biohaven”) are pleased to announce that Biohaven has acquired the … Read More»
Biohaven Raises $ 4.1 Million In First Tranche Of Private Placement. Portage Invests $ 2.5 Million
Toronto, Ontario, August 11, 2015 – Portage Biotech Inc. (“Portage” or “the Company”) (OTC: PTGEF, Canadian Securities Exchange: PBT.U) is pleased to announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven), in which Portage holds 54% … Read More»
Biohaven Announces IND Filing For BHV-0223 For Phase 1 Clinical Testing
Toronto, Ontario, July 23, 2015 – Portage Biotech Inc. (“Portage”) (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce that Biohaven has filed an … Read More»
Biohaven Issued Notice Of Allowance:Glutamate Agents In The Treatment Of Mental Disorders
Intellectual property licensed from Yale University protects the use of certain glutamate modulating agents in the treatment of Generalized Anxiety Disorder Toronto, Ontario, May 2, 2014 – Portage Biotech Inc. (“Portage”) (OTCQB: PTGEF, … Read More»
Biohaven Receives Positive Response From FDA To Its Pre-IND Meeting Request
Biohaven filed a pre-IND meeting request with the FDA regarding lead investigational agent BHVN-0223, receives written response in lieu of an in-person meeting Toronto, Ontario, December 15, 2014 – Portage Biotech Inc. (“Portage”) (OTCQB: PTGEF, … Read More»
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- Next Page »